Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of 13.36% and Operating profit at -47.33% over the last 5 years
2
The company has declared negative results for the last 4 consecutive quarters
3
With ROE of 3.97%, it has a very expensive valuation with a 4.03 Price to Book Value
Stock DNA
Pharmaceuticals & Biotechnology
CNY 109,661 Million (Mid Cap)
101.00
NA
0.00%
-0.10
3.52%
54.11
Revenue and Profits:
Net Sales:
178 Million
(Quarterly Results - Sep 2025)
Net Profit:
8 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
23.59%
0%
23.59%
6 Months
13.48%
0%
13.48%
1 Year
70.71%
0%
70.71%
2 Years
46.02%
0%
46.02%
3 Years
59.58%
0%
59.58%
4 Years
47.17%
0%
47.17%
5 Years
0%
0%
0.0%
Xiangyu Medical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
13.36%
EBIT Growth (5y)
-47.33%
EBIT to Interest (avg)
60.15
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.14
Sales to Capital Employed (avg)
0.31
Tax Ratio
4.11%
Dividend Payout Ratio
36.36%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
11.10%
ROE (avg)
8.00%
Valuation key factors
Factor
Value
P/E Ratio
101
Industry P/E
Price to Book Value
4.03
EV to EBIT
413.12
EV to EBITDA
115.19
EV to Capital Employed
4.42
EV to Sales
10.43
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
1.07%
ROE (Latest)
3.97%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY
Sep'25
Sep'24
Change(%)
Net Sales
178.00
168.80
5.45%
Operating Profit (PBDIT) excl Other Income
-5.20
12.20
-142.62%
Interest
1.60
0.80
100.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
8.40
16.80
-50.00%
Operating Profit Margin (Excl OI)
-29.50%
11.80%
-4.13%
USD in Million.
Net Sales
YoY Growth in quarter ended Sep 2025 is 5.45% vs -18.49% in Sep 2024
Consolidated Net Profit
YoY Growth in quarter ended Sep 2025 is -50.00% vs -76.57% in Sep 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
740.00
736.70
0.45%
Operating Profit (PBDIT) excl Other Income
96.00
193.20
-50.31%
Interest
5.90
4.00
47.50%
Exceptional Items
-1.80
-3.20
43.75%
Consolidate Net Profit
102.90
228.30
-54.93%
Operating Profit Margin (Excl OI)
73.00%
235.60%
-16.26%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 0.45% vs 51.62% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -54.93% vs 85.16% in Dec 2023
About Xiangyu Medical Co., Ltd. 
Xiangyu Medical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






